Loading the records…
Loading the records…
HR11024, introduced by Rep. Onder (R-MO) and cosponsored by Rep. Bacon (R-NE), would mandate health insurance coverage for allergy and asthma diagnostic testing and allergen immunotherapy. The bill is in early stages, referred to the House Energy and Commerce Committee, with no funding specified. The direct market impact is limited to a slight cost increase for insurers and a marginal volume boost for diagnostic laboratories.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill's impact on publicly traded companies is minimal. For health insurers like UnitedHealth Group, the mandate adds a small cost pressure that is easily absorbed given their $447.6B revenue base and 2.7% margin. Diagnostic companies like Quest Diagnostics ($DGX) may see a slight uptick in allergy test volumes, but this represents a fraction of their total testing revenue. No material stock movement is expected from this legislation alone. Investors should monitor committee activity and any broader healthcare reform packages that might incorporate this mandate. Without further legislative progress, the bill does not warrant portfolio changes.
On November 12, 2026, Rep. Robert F. Onder (R-MO-3) introduced HR11024, a bill to amend the Public Health Service Act to require group health plans and health insurance issuers in the group and individual markets to provide coverage for allergy and asthma diagnostic testing and allergen immunotherapy. The bill has been referred to the House Committee on Energy and Commerce and currently has one cosponsor, Rep. Don Bacon (R-NE-2). As an early-stage authorization bill, it does not appropriate any funds; it imposes a coverage mandate on private insurers.
The money trail here is indirect: the bill does not allocate federal dollars but shifts costs to private health insurers, which must cover these services. Insurers may pass costs to employers and individuals through premiums. The primary financial beneficiaries are diagnostic laboratories and immunotherapy product suppliers, as mandated coverage increases utilization. However, the bill does not specify pricing or reimbursement rates, so the revenue impact on any single company is uncertain.
Convergence: No related signals or procurement actions were provided in the context, so this bill stands alone as a narrow healthcare coverage mandate. Its passage probability is low given early stage, single-party sponsorship, and no companion bill in the Senate.
Structural winners are diagnostic testing companies like Quest Diagnostics ($DGX) and LabCorp ($LH), which would see incremental volume in allergy testing. Losers are health insurers like UnitedHealth Group, which face higher claims costs, though the impact is small relative to their massive revenue bases. No pure-play allergy immunotherapy companies are publicly traded in the US, limiting direct equity exposure.
The legislative path requires committee markup, House passage, Senate introduction and passage, and presidential action. Given the 119th Congress is in its second session, the window for passage is narrow without broader bipartisan support or inclusion in a larger healthcare package.
Matched on shared policy language across AI analyses, with ticker & timing weight
MERCK SHARP & DOHME LLC: $1.8B Department of Health and Human Services Contract Vehicle
OHIO DEPARTMENT OF MEDICAID: $28.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $1.2B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $2.1B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.0B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.4B Department of Health and Human Services Federal Award
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →